Summary
This study is testing a new investigational medicine called JNJ-95804306 in people with certain blood cancers that have come back after treatment (relapsed) or have not responded to treatment (refractory). The study is recruiting adults with conditions including:
- Acute myeloid leukaemia (AML)
- Myelodysplastic syndromes (MDS)
- Chronic lymphocytic leukaemia (CLL)
- Small lymphocytic lymphoma (SLL)
The study has two parts.
Part 1 (Dose Escalation)
Researchers will test different dose levels of JNJ-95804306 to find the safest and most suitable dose. Participants will be closely monitored for side effects and how well they tolerate the treatment.
Part 2 (Dose Expansion)
Once a suitable dose has been identified, more participants will receive JNJ-95804306 to further assess its safety and to see how well it works against these blood cancers.
At sites outside the United States, JNJ-95804306 may be given on its own or together with standard treatments for AML, MDS, CLL or SLL. At United States sites, JNJ-95804306 will be given on its own.
Researchers will also study how the body processes JNJ-95804306 and whether the treatment can help reduce or control cancer. The information collected will help determine whether JNJ-95804306 should be studied further in future clinical trials.
Conditions
This trial is treating people with relapsed or refractory blood cancers, include acute myeloid leukaemia, high-risk myelodysplastic syndrome, chronic lymphocytic leukaemia, small lymphocytic lymphoma or non-Hodgkin lymphoma